Endoxifen Hydrochloride

Phase 1Small molecule

Endoxifen Hydrochloride is one of 4 small molecule programs targeting Breast Carcinoma in Situ. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast Carcinoma in SituActive, not recruiting

Her2/neu PositiveActive, not recruiting

Breast Carcinoma in SituPhase 1

Active, not recruiting

Her2/neu PositivePhase 1

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Breast Carcinoma in Situ

#DrugCompanyPhaseTrials

Aromasin

Keytruda

1 3

Tykerb

Novartis

Preclinical

1 4

Endoxifen Hydrochloride

NNational Cancer Institute (NCI)

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Recurrent Breast Carcinoma

NCT02311933

Q3 2027

Phase 1Active, not recruiting

Breast Carcinoma in Situ

NCT03317405

Clinical

Trials by Indication[1]

Recurrent Breast Carcinoma1 trial

A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02311933·81 enrolled

Breast Carcinoma in Situ1 trial

Phase I Trial of Endoxifen Gel Versus Placebo Gel in Women Undergoing Breast Surgery

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03317405·32 enrolled

HER2/Neu Positive1 trial

Phase I Study of Z-Endoxifen as a Hormonal Therapy for Breast Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT01327781·62 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Endoxifen Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Endoxifen Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Endoxifen Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNational Cancer Institute (NCI)

Endoxifen Hydrochloride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Trials by Indication[1]

Recurrent Breast Carcinoma1 trial

Breast Carcinoma in Situ1 trial

HER2/Neu Positive1 trial

References

Drug Info

Quick Facts

Related News